Tilray Brands, Inc. (TLRY) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended November 30, 2025 (Fiscal Q2 2026). Tilray Brands operates as a global lifestyle consumer products company with four primary segments: Cannabis, Beverage, Distribution, and Wellness. The company is headquartered in Leamington, Ontario, and New York. A 1-for-10 reverse stock split became effective on December 2, 2025; all share and per-share data in this report have been retrospectively adjusted to reflect this split.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Net Revenue | $217.5 million | $211.0 million | $427.0 million | $411.0 million |
| Gross Profit | $57.5 million | $61.2 million | $115.0 million | $120.9 million |
| Gross Margin | 26.4% | 29.0% | 26.9% | 29.4% |
| Operating Loss | ($22.3 million) | ($42.2 million) | ($20.2 million) | ($78.8 million) |
| Net Loss | ($43.5 million) | ($85.3 million) | ($42.0 million) | ($119.9 million) |
| Adjusted EBITDA | $8.4 million | $9.0 million | $18.5 million | $18.4 million |
| Cash & Marketable Securities | $291.6 million (as of Nov 30, 2025) | |||
| Total Debt (Current + Long-term) | ~$174.2 million (excluding convertible debentures) | |||
| Convertible Debentures (TLRY 27) | $100.0 million principal outstanding |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated net revenue increased 3% quarter-over-quarter and 4% year-to-date, driven primarily by the Distribution and International Cannabis segments.
- Segment Performance:
- Beverage: Revenue declined 21% QoQ due to category challenges and "Project 420" optimization (SKU rationalization). Gross margin compressed to 31% from 40%.
- Cannabis: Revenue grew 3% QoQ. International cannabis revenue surged 36% QoQ, offsetting declines in wholesale channels. Gross margin improved to 39%.
- Distribution: Revenue increased 26% QoQ, driven by competitive pricing and favorable foreign exchange impacts.
- Expense Reduction: Total operating expenses decreased 23% QoQ. This was largely due to an 81% reduction in amortization expenses (following prior-year impairments) and a $15.0 million gain from the revaluation of contingent consideration related to the Montauk acquisition.
- Non-Operating Items: Foreign exchange losses decreased significantly compared to the prior year. The company recognized a $1.8 million loss on assets held for sale (Fort Collins warehouse) and a $0.5 million gain on the exchange of TLRY 27 Notes.
Guidance, Outlook, and Risks
- Strategic Initiatives: Management continues to execute "Project 420" in the beverage segment to optimize SKUs, geography, and distributors, aiming to realize $33 million in synergies (currently $27.2 million achieved). The company plans to complete this optimization in Q4 FY2026.
- Capital Structure: The company completed its $250 million At-The-Market (ATM) program, raising $76.6 million in gross proceeds during the six-month period. Management intends to opportunistically exchange equity for TLRY 27 Notes prior to their June 2027 maturity.
- Regulatory Risks:
- U.S. Hemp Legislation: New federal legislation enacted in November 2025 bans the production/sale of hemp-derived Delta-9 products effective November 2026. Management anticipates potential regulatory evolution prior to this date.
- Rescheduling: Ongoing uncertainty regarding the U.S. federal rescheduling of cannabis from Schedule I to Schedule III impacts long-term U.S. market strategy.
- Self-Insurance: The company has transitioned certain real property assets to a self-insurance model, increasing exposure to potential property-related losses.
Investor Verification Checklist
- Reverse Stock Split Impact: Verify that all historical share counts and per-share metrics in external models have been adjusted for the 1-for-10 split effective December 2, 2025.
- Beverage Margin Trajectory: Monitor the timeline for realizing the remaining $5.8 million in Project 420 synergies and the impact of SKU rationalization on future revenue growth.
- International Cannabis Permits: Assess the stability of international revenue growth, which is subject to export/import permit delays (notably in Germany and other EMEA markets).
- Debt Maturity Profile: Review the $100 million TLRY 27 convertible notes maturing in June 2027 and the company's ability to refinance or exchange them given current stock price volatility.
- Regulatory Timeline: Track the implementation date of the U.S. hemp-derived Delta-9 ban (Nov 2026) and any potential executive orders or legislative changes that may alter the landscape.